Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin

• Główni autorzy: Mikko Pyykönen (Autor), Miika Linna (Autor), Markku Tykkyläinen (Autor), Eric Delmelle (Autor), Tiina Laatikainen (Autor)
• Format: Książka
• Wydane: BMC, 2021-12-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract Background Anticoagulant therapies are used to prevent atrial fibrillation-related strokes, with warfarin and direct oral anticoagulant (DOAC) the most common. In this study, we incorporate direct health care costs, drug costs, travel costs, and lost working and leisure time costs to estima...